Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis
1. Reponex Pharmaceuticals gets approval for pivotal RNX-011 clinical trial. 2. Trial addresses life-threatening secondary peritonitis with high mortality rates. 3. Study aims to reduce postoperative complications through unique therapy. 4. Approval marks a significant milestone, enhancing company’s partnership prospects. 5. 32 patients to be enrolled; first patient expected in Q4 2025.